non-invasive prenatal testing -...

18
- 7/15/2015 Non invasive Prenatal Screening Tiffiney Carter, MS CGC Lauren Westerfield, MS CGC Certified Genetic Counselors Department of Molecular and Human Genetics Baylor College of Medicine Disclosure Tiffiney Carter is a faculty member of the Department of Molecular and Human Genetics at Baylor College of Medicine Lauren Westerfield is a genetic counselor at the Department of Molecular and Human Genetics at Baylor College of Medicine The Medical Genetics Laboratories in this department offer extensive genetic laboratory testing, including chromosomal microarray analysis (CMA) and NIPS, and derive revenue from this activity We do not receive personal revenue from this activity. Objectives Attendees will be able to: describe how non-invasive prenatal screening (NIPS) is performed list the major indications for NIPS describe appropriate follow-up counseling for an abnormal NIPS result 1

Upload: lecong

Post on 28-Feb-2018

225 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

-

7/15/2015

Non invasive Prenatal Screening

Tiffiney Carter, MS CGC

Lauren Westerfield, MS CGC

Certified Genetic Counselors

Department of Molecular and

Human Genetics

Baylor College of Medicine

Disclosure

• Tiffiney Carter is a faculty member of the Department of Molecular and Human Genetics at Baylor College of Medicine

• Lauren Westerfield is a genetic counselor at the Department of Molecular and Human Genetics at Baylor College of Medicine

• The Medical Genetics Laboratories in this department offer extensive genetic laboratory testing, including chromosomal microarray analysis (CMA) and NIPS, and derive revenue from this activity

• We do not receive personal revenue from this activity.

Objectives

Attendees will be able to:

• describe how non-invasive prenatal screening (NIPS) is performed

• list the major indications for NIPS

• describe appropriate follow-up counseling for an abnormal NIPS result

1

Page 2: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

7/15/2015

GENETIC COUNSELING

So what is a genetic counselor?

• Health care professionals that work as a member of a multidisciplinary team

– Specialized masters degree

– Experience in medical genetics and counseling

• Risk Assessment

• Education

• Support

• Facilitate Decision Making

Where we practice

– Hospitals and affiliated clinics

– University medical centers

– Clinical laboratories

– Research

– Telemedicine

– Nonprofit organizations

2

Page 3: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

How to find services for your patient

7/15/2015

– National Society of Genetics Counselors “Find a Genetic Counselor”, http://www.nsgc.org

– American Board of Genetic Counseling, http://www.abgc.net

– Local specialty clinics such as Maternal Fetal Medicine, Cancer/Oncology, Cardiology/Cardiovascular disease, children’s hospitals

GENETICS REFRESHER

3

Page 4: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

7/15/2015

Common chromosome anomalies

• Aneuploidy

– Monosomy, trisomy, tetrasomy

– Most common are trisomy 13, trisomy 18, trisomy 21, monosomy X, and Klinefelter syndrome (XXY)

• Polyploidies

– Triploidy, tetraploidy

• Copy number variants

– Duplications

– Deletions

• Abnormalities can be balanced (reciprocal translocation, inversion) or unbalanced

These are generally sporadic conditions – your patient may have no obvious risk factors

Goals of Prenatal Diagnosis and Counseling

• Assess the health of a fetus

• Determine specific risks to fetus

• Manage the pregnancy

• Plan for complications at birth

• Evaluate prenatal diagnostic options

• Diagnosis fetus when desired and possible

• Educate family about diagnosis, likely outcomes, potential and management options

• Discuss risks, benefits, and uncertainties

• Explore family concerns

• Provide risk assessment for other family members

• Provide psychosocial support and follow-up

4

Page 5: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

18

7/15/2015

Traditional maternal serum screening (MSS)

• Available at specific gestational age

• Targets the most common trisomies – 21 and

• Influence by maternal factors – age, ethnicity, accurate dating, diabetes, number of fetuses

Detection Rates for Maternal serum screening (MSS) for Down syndrome

Method Screening

Maternal Age (MA)

Nuchal translucency (NT) alone

Weeks performed

___

Detection Rate for Down syndrome

30%

64-70%

First trimester screening (NT + analytes)

11-13+6 wks 91%

First trimester screening (NT + analytes + nasal bone)

11-13+6 wks 95%

Second trimester screening 15-21+6 wks Triple screen 70% Quadruple screen 75-81% Penta screen 83%

False positive rates range from 2-5%.

NON-INVASIVE PRENATAL SCREENING (NIPS)

5

Page 6: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

Technological Evolution

7/15/2015

cffDNA first described 1997

Research phase

2011 Clinical Launch, October 2011 - Trisomy 21

2012 Trisomy 18 and 13, February 2012 Twin gestations, May 2012 Presence of Y chromosome, August 2012

2013 Sex chromosome aneuploidy, triploidy/vanishing twin, February 2013

Expanded NIPS launches*, October 2013 2014

3 additional microdeletions**, July 2014

2015

Methods of analysis

• Analysis Methods/Proprietary Algorithm:

– Z-score - Sequenom

– Normalized Chromosome Value (NCV) - Verinata

– Digital Analysis of Selected Regions (DANSR) – Ariosa

– Next-generation Aneuploidy Testing Using SNPs (NATUS) – Natera

• Reporting

– positive/negative

– “low risk”/”high risk”

6

Page 7: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

HOW DOES IT WORK?

7/15/2015

Extra Chromosome 21

Fragments Contributed by

Fetal Trisomy 21

Count the fragments (N) from each chromosome: – N is proportional to the size of the

chromosome – N is consistent from sample to

sample – N is consistent from patient to

patient

If there is fetal trisomy, there is a relative small increase in the number of fragments from that chromosome

Requires various normalization steps

Fetal Fraction can affect test performance

Fetal fraction = 10-20% between 10-21 weeks

Increased fetal fraction Decreased fetal fraction

Crown-rump length Maternal weight (BMI)

PAPP-A African/Caribbean descent

Beta-hCG

Smoking

Intrauterine growth restriction

Twins: overall ~30% increase, but 50% decrease for each twin

Aneuploidy:

Ashoor et al, Ultrasound Obstet Gynecol 2013; 41: 26–32 Taglauer et al, Placenta 2014;28:S64-S68

decrease in T13, T18, mono X increase in T21

“Traditional NIPS

Chromosome DR (%) FPR

Trisomy 21 99.0 0.08 (18 studies) (98.2 – 99.6) (0.03 – 0.14)

Trisomy 18 96.8 0.15 (15 studies) (94.5 – 98.4) (0.08 – 0.25)

Trisomy 13 92.1 0.20 (11 studies) (85.9 – 96.7) (0.04 – 0.46)

Monosomy X 88.6 0.12 (12 studies) (83.0 – 93.1) (0.05 – 0.24)

Other sex chr. aneuploidy 93.8 0.12 (9 studies) (85.9 – 98.7) (0.02 – 0.28)

Twin pregnancy trisomy 21 94.4 0 (3 studies) (74.2 – 99.0) (0.00 – 1.84)

Gil et al. Fetal Diagn Ther 2014;35:156-173

7

Page 8: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

NIPS for Microdeletion syndromes and other trisomies

7/15/2015

Natera Sequenom/Quest Illumina

22q11.2 deletion (DiGeorge) ● ● ●

15q11-13 deletion (Angelman/Prader-Willi) ● ● ●

5p- (Cri-du-chat) ● ● ●

4p- (Wolf-Hirschhorn) ● ●

1p36 deletion ● ● ●

8q- (Langer-Giedion) ●

11q- (Jacobsen) ●

Trisomy 9 ●

Trisomy 16 ● ●

Trisomy 22 ●

• Currently offered in the US by five companies • Different reporting and ordering algorithms

Expanded NIPS

Microdeletions are rare – their incidence is not linked to maternal age • Limited validation studies, mostly case reports and proof of concept

studies

The larger the deletion, the easier it is to detect. • Deletions <7 Mb, sensitivity estimated at 60-85%

• Deletions >7 Mb (which might be cytogenetically visible), sensitivity estimated at >85%

First purely clinical outcome study

Deletion True Positive DR(%)

Suspected DR(%)

False Positive DR(%)

22q11.2 23/32 (71.9%)

8/32 (25.0%)

unknown

15q 4/9 (44.0%)

1/9 (11.1%)

unknown

1p36 3/5 (60.0%)

1/5 Lost to follow-up

1/5 (20.0%)

5p 4/6 (66.7%)

___ 2/6 (33.3%)

4p 1/1 (100%)

___ ___

11q 1/1 (100%)

___ ___

8q ___ 1/1 ___

Hume et al. 2015. Clinical outcome of subchromosomal events detected by whole-genome non-invasive prenatal testing.

8

Page 9: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

NIPS: Concerns with microdeletions

7/15/2015

Limited to recurrent, well-characterized deletions

• not designed for smaller or atypically located ones

Variability in detection by company

• Fetal fraction, sequence reads, etc all play a role, but algorithms vary

Potential to incidentally diagnose a parent

• 8-28% of 22q11.2 deletions are inherited and parent may not know they’re affected

• 25 of 55 identified microdeletions in 2015 Sequenom study had maternal contribution

Value of NIPS

• A step towards the ultimate goal of non-invasive amniocentesis/chromosome microarray, but not a replacement for diagnostic testing

– Positive result can help direct management, but does not confirm diagnosis.

– Negative results does not exclude condition or possible other chromosome rearrangement

• When multiple ultrasound anomalies are seen, karyotype with addition of chromosome microarray has the highest diagnostic yield

However….

A test can have both a high sensitivity and specificity without being a good predictor of whether the

condition is actually present

It’s all about the PPV!

9

Page 10: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

-

7/15/2015

Total population Condition present Condition absent

Test

ou

tco

me Test positive True Positive False Positive

Test negative False Negative True Negative

• POSITIVE PREDICTIVE VALUE = True positives/All positive tests

• NEGATIVE PREDICTIVE VALUE = True negatives/All negative tests

Calculating PPV for NIPS

• Hypothetical population of 35 y.o. women = 100,000 births annually

Incidence

Down syndrome

1/250

Trisomy 18

1/2000

Trisomy 13

1/5000

Affected fetuses 400 50 20

Sensitivity 99.5% 98.0% 90.0%

Specificity 99.9% 99.6% 99.8%

Total test positives 498 449 218

True test positives 398 49 18

False positives 100 400 200

Positive predictive value 80% 11% 8%

NIPS: Discrepant Results Etiologies

• No test is perfect:

– Test statistics and fetal fraction

• 2.6 – 5.4% test failure (many due to low FF)

• Lab error

• Pregnancy factors

– Confined placental mosaicism ~1%?

• NIPS measures the genome of the entire cytotrophoblast

– True fetal mosaicism

– Co-twin demise (“vanishing twin”)

• Maternal factors

– sex chromosome abnormality (may increase with age)

– marker chromosome

– deletion or duplication

– tumor with high levels of cffDNA

10

Page 11: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

PPV implications for the future

7/15/2015

• The use of NIPS continues to expand:

– General (low risk) population screening

– Rarer conditions such as microdeletion syndromes

• The positive predictive value is dependent on the background incidence of the condition being tested.

– High risk populations/common conditions = higher PPV

– Low risk populations/rare conditions = lower PPV

Even if sensitivity and specificity are the same!

OFFERING TESTING AND DISCUSSING RESULTS

For those women who are at increased risk of a child with a prenatally

diagnosable disorder with Mendelian pattern of inheritance,

microdeletion syndrome, and some other conditions, amniocentesis or

CVS would still be indicated.

11

Page 12: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

7/15/2015

Guidelines for offering

NIPS can be offered to patients at increased risk of fetal aneuploidy

• Maternal age 35 years or older at delivery

• Fetal ultrasound findings indicating an increased risk of aneuploidy

• History of a prior pregnancy with aneuploidy

• Abnormal maternal serum screen for aneuploidy (first trimester,

sequential, integrated, quad)

• Parental balanced robertsonian translocation with increased risk of fetal

trisomy 13 or trisomy 21

ACOG and SMFM Committee Opinion 640, 2015 ACMG statement on NIPS for fetal aneuploidy, 2013

Guidelines for offering

• Conventional screening methods remain the most appropriate first-line choice for the general obstetric population*

• NIPS is not recommended for women with multiple gestations, because it has not been sufficiently evaluated in these groups**

• Routine NIPS screening for microdeletion syndromes should not be performed

ACOG and SMFM Committee Opinion 640, 2015 ACMG statement on NIPS for fetal aneuploidy, 2013

Other recommendations

• Parallel or simultaneous testing with multiple screening methodologies for aneuploidy is not cost-effective and should not be performed.

• Unreportable, indeterminate, or uninterpretable (“no call”) results:

– Increased risk of aneuploidy

– receive further genetic counseling and be offered ultrasound evaluation and diagnostic testing

ACOG and SMFM Committee Opinion 640, September 2015

12

Page 13: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

Other

7/15/2015

• NIPS does not replace the utility of a first-trimester ultrasound examination, which has been proven to be useful for:

– accurate gestational dating

– assessment of the nuchal translucency region to identify a fetus at increased risk for a chromosome abnormality

– identification of twins and higher-order pregnancies, placental abnormalities, and congenital anomalies.

• NIPS does not screen for open neural tube defects. Maternal serum α-fetoprotein testing should still be offered at 15–20 weeks gestation to screen for open neural tube defects even when NIPS is performed.

ACMG statement on NIPS for fetal aneuploidy, 2013 ACOG and SMFM Committee Opinion 640, September 2015

Talking to patients

Pre-test discussion

• Benefits and limitations – this is a screening test and does not look for all genetic conditions

• Explain test in context of clinical situation – what will a positive result mean? A negative result?

• Cost

• NIPS is NOT just a gender test

Talking to patients

Post-test discussion - Negative result

• Reassuring, but does not eliminate risk

– Does not reduce risk of other abnormalities

– Residual risk of a chromosome abnormality in the case of an abnormal serum screen and normal NIPS is reported to be about 2%

• Still recommend msAFP and anatomy ultrasound

13

Page 14: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

Talking to patients

7/15/2015

Post-test discussion - Positive result

• Increased risk, but is not diagnostic – Provide individualized risk if possible (PPV)

• Refer for genetic counseling

• Referrals to other specialists as needed – MFM, echo, MRI, fetal centers, neo, etc

• Confirmatory testing (CVS, amniocentesis, neonatal studies) is recommended

• Management decisions, including termination, should not be based on NIPS results alone

CASE EXAMPLES

Case 1

• 35 y.o. G2P0010 who conceived via in-vitro fertilization. No preimplantation genetic screening performed

– Family history noncontributory

– Declined genetic screening in the first trimester

• Second trimester anatomy ultrasound at 19 weeks detected bilateral ventriculomegaly and a heart defect

• Fetal echo confirmed complete balanced AV canal defect. Additional findings included a two-vessel cord.

14

Page 15: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

AV canal defects

7/15/2015

Etiology

• 40-50% - Down syndrome

• 32% - nonsyndromic

• 17.5% - other genetic syndrome

– Deletion 8p, Noonan syndrome, VACTERL, Ellis-van Creveld, etc.

Outcome

• NIPS was drawn at 19 weeks and results were positive for trisomy 21

• Patient elected to continue pregnancy and due to NIPS results received consultation with the pediatric Down syndrome clinic during her pregnancy

• Confirmatory testing planned at delivery

Case 2

• 39 y.o. G2P1001 who was referred at 28w2d GA for fetal cardiac anomaly – Ultrasound findings consistent with Tetralogy of Fallot. No other

abnormalities seen

• Prior NIPS drawn at 12 weeks was – Negative for aneuploidy of 13, 18, 21, X, or Y,

– No evidence of 22q, 15q, 5p, or 1p microdeletion

• Family history noncontributory

• Fetal echo at 28 weeks confirmed Tetralogy of Fallot with pulmonary atresia and a right aortic arch

15

Page 16: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

Tetralogy of Fallot

7/15/2015

• 4 to 5 per 10,000 live births

• 7 to 10% of cases of congenital heart disease

• Approximately 15 percent of patients with TOF present with associated syndromes: – Down syndrome

– Alagille syndrome

– DiGeorge and velocardiofacial syndromes (deletion on chromosome 22q11).

• Pulmonary atresia and/or arch anomaly more significantly associated with DiGeorge/22q11.2 deletion syndrome

Outcome

• Delivered at 33w GA

• Sample collected at birth and sent for CMA

– 2.247 Mb deletion at 22q11.2

• False negative NIPS

– Best option for prenatal testing based on ultrasound would have been CMA

• Maternal FISH was negative for the deletion

• Paternal genetic status unknown at this time

Case 3

• 15 y.o. G1P0 who was referred at 35w0d gestation due to multiple fetal brain anomalies, possibly consistent with Dandy-Walker malformation

• Family history noncontributory

• Patient offered and declined amniocentesis. Expanded NIPS drawn

• Results: increased risk for trisomy 9 – No data available to provide a positive predictive value for trisomy 9

16

Page 17: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

Trisomy 9

7/15/2015

• Non-mosaic or complete trisomy 9 is a lethal diagnosis, with most fetuses dying prenatally or during the early postnatal period.

– few cases reported to have been detected by prenatal ultrasound.

– most cases result in first trimester spontaneous miscarriage

– longest reported surviving case of full trisomy 9 less than 1 month.

• Most of individuals that survive to term are mosaic.

– Multiple malformations, dysmorphic features, severe developmental and intellectual disability

Again offered amniocentesis for diagnostic testing and to inform neonatal management. Patient declined. Postnatal genetics evaluation was arranged.

Outcome

• Delivered at 40 weeks 5 days gestation

• Sample collected for chromosome analysis

– karyotype: 46,XX normal female

• CMA: 4.544 Mb deletion of 6p25.3p25.1 including the FOXC1 gene.

– Deletions of FOXC1 have been reported in patients with Axenfeld-Rieger syndrome, type 3.

– terminal deletion is within the chromosome 6pter-p24 deletion syndrome region

– Similar sized deletions have been reported in patients with intellectual disability, developmental delay, ocular abnormalities, hearing loss and a characteristic facial appearance.

Predictions for the future

• Additional conditions

• Additional populations

• Technology evolution

– intact fetal cells

– Non-invasive microarray/karyotype

Things will continue to evolve at a rapid pace

17

Page 18: Non-invasive Prenatal Testing - geneticsconferencetx.comgeneticsconferencetx.com/newsite/Documents/Westerfield_Carter_7-18... · • describe how non-invasive prenatal screening

7/15/2015

References

• Benn P, Borrell A, Chiu RW, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2015 May 13. doi: 10.1002/pd.4608. [Epub ahead of print]

• Dondorp W, de Wert G, Bombard Y, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet. 2015 Mar 18. doi: 10.1038/ejhg.2015.57. [Epub ahead of print]

• The American College of Obstetricians and Gynecologists. The Society for Maternal Fetal Medicine. Noninvasive Prenatal Testing for Fetal Aneuploidy. Committee Opinion 545. Obstet Gynecol. 2012 Dec;120(6):1532

• Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genetics in Medicine 2013 May;15(5):395-8

• The American College of Obstetricians and Gynecologists. The Society for Maternal Fetal Medicine. Cell-free DNA Screening for Fetal Aneuploidy. Committee Opinion 640, September 2015. Obstet Gynecol. [epub ahead of print]

• Digilio MC, Marino B, Toscano A, et al. Atrioventricular canal defect without Down syndrome: A heterogeneous malformation. J Med Genet , 1999;85(2):140-46

References cont’d

• Rauch R, Hofbeck M, Zweier C, et al. Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot. Am J Med Genet 2010; 47:321.

• Goldmuntz E, Clark BJ, Mitchell LE, et al. Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll Cardiol 1998; 32:492.

• Zhao C, Tynan J, Ehrich M, et al. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clin Chem. 2015 Apr;61(4):608-16.

• Bruns DA, Campbell E. Twenty-five additional cases of trisomy 9 mosaic: Birth information, medical conditions, and developmental status. Am J Med Genet A. 2015 May;167A(5):997-1007.

• Ferguson-Smith MA, Yates JR. Maternal age-specific risks for chromosome aberrations and factors influencing them: a report of a collaborative European study on 52, 965 amniocenteses. Prenat Diagn 1984;4:5-54

• Hume JH, Wardrop J, Boomer T, et al. Clinical outcome of subchromosomal events detected by whole-genome non-invasive prenatal testing. Accepted and pending publication.

THANK YOU!

18